Trimeprazine/Prednisolone

Trimeprazine/Prednisolone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 58 adverse event reports referencing Trimeprazine/Prednisolone, including 6 reports in which the animal died — a 1030.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Trimeprazine/Prednisolone. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Trimeprazine/Prednisolone reports are Dog (57 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (5), Retriever - Golden (5), Shih Tzu (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Trimeprazine/Prednisolone are Lethargy (see also Central nervous system depression in 'Neurological') (14), Other abnormal test result NOS (14), Vomiting (13), Diarrhoea (8). Of the 59 reports with a coded outcome, Recovered/Normal is the leading category at 42.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Trimeprazine/Prednisolone.